Antonio Scilimati Selected Research

Antonio Scilimati Research Topics

Disease

6	Ovarian Neoplasms (Ovarian Cancer) 05/2022 - 03/2014
5	Neoplasms (Cancer) 05/2022 - 01/2008
5	Neuroinflammatory Diseases 12/2017 - 01/2012
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/2020 - 03/2017
3	Pain (Aches) 02/2019 - 01/2015
2	Inflammation (Inflammations) 11/2020 - 01/2017
2	Parkinson Disease (Parkinson's Disease) 03/2017 - 03/2017
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2015 - 03/2006
2	Heart Failure 01/2010 - 02/2005
2	Colonic Neoplasms (Colon Cancer) 01/2010 - 01/2008
1	Frailty 01/2022
1	Bone Diseases (Bone Disease) 01/2022
1	Bone Resorption 01/2022
1	Bone Fractures (Bone Fracture) 01/2022
1	Cantu syndrome 01/2022
1	Drug-Related Side Effects and Adverse Reactions 08/2021
1	Diffuse Intrinsic Pontine Glioma 01/2021
1	Mental Disorders (Mental Disorder) 11/2020
1	Ischemic Stroke 10/2020
1	Stroke (Strokes) 10/2020
1	Hemolysis 02/2019
1	Multiple Myeloma 02/2019
1	Plasma Cell Neoplasms 02/2019
1	Osteoporosis 10/2018
1	Neuroblastoma 03/2017
1	Glioma (Gliomas) 03/2017
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2017
1	Carcinogenesis 01/2015
1	Ovarian Epithelial Carcinoma 06/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2012
1	Type 2 Diabetes Mellitus (MODY) 01/2010
1	Obesity 01/2010
1	Cachexia 01/2010
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2010
1	Depressive Disorder (Melancholia) 01/2010
1	Overactive Urinary Bladder (Overactive Bladder) 01/2010
1	Premature Obstetric Labor (Premature Labor) 01/2010
1	Neoplasm Metastasis (Metastasis) 01/2008
1	Atherosclerosis 02/2005
1	Dyslipidemias (Dyslipidemia) 02/2005
1	Dehydration (Water Stress) 09/2004

Drug/Important Bio-Agent (IBA)

5	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 05/2022 - 01/2017
5	mofezolacIBA 10/2020 - 01/2017
4	Cyclooxygenase 1IBA 10/2020 - 06/2014
3	Biomarkers (Surrogate Marker)IBA 05/2022 - 06/2014
3	Pharmaceutical PreparationsIBA 01/2022 - 01/2010
3	Diphosphonates (Bisphosphonates)IBA 01/2022 - 10/2018
2	Fluorescent Dyes (Fluorescent Probes)IBA 05/2022 - 10/2019
2	Dihydroxyphenylalanine (Dopa)IBA 03/2017 - 03/2017
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2012 - 03/2006
2	Messenger RNA (mRNA)IBA 01/2012 - 01/2008
1	Protein Isoforms (Isoforms)IBA 05/2022
1	farnesyl pyrophosphate (farnesyl diphosphate)IBA 01/2022
1	Zoledronic Acid (Zometa)FDA Link 08/2021
1	Adenosine Triphosphate (ATP)IBA 08/2021
1	Dopamine AntagonistsIBA 01/2021
1	dipinacoline glutamateIBA 01/2021
1	TIC10 compoundIBA 01/2021
1	Radioisotopes (Radionuclides)IBA 02/2020
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 02/2020
1	indium-111-octreotideIBA 02/2020
1	Ga(III)-DOTATOCIBA 02/2020
1	Peptide Receptors (Peptide Receptor)IBA 02/2020
1	Proteasome InhibitorsIBA 02/2019
1	Proteins (Proteins, Gene)FDA Link 02/2019
1	MutagensIBA 02/2019
1	Bortezomib (Velcade)FDA Link 02/2019
1	LigandsIBA 02/2019
1	AcidsIBA 10/2018
1	Dinoprostone (PGE2)FDA Link 12/2017
1	CyclodextrinsIBA 03/2017
1	Dosage Forms (Dosage Form)IBA 03/2017
1	Levodopa (L Dopa)FDA LinkGeneric 03/2017
1	Glial Fibrillary Acidic ProteinIBA 01/2017
1	NF-kappa B (NF-kB)IBA 01/2017
1	CalciumIBA 01/2017
1	S-Adenosylmethionine (Ademetionine)IBA 01/2017
1	LipopolysaccharidesIBA 01/2017
1	Neuroprotective AgentsIBA 01/2017
1	Plant ExtractsIBA 01/2016
1	EnzymesIBA 03/2014
1	EtoricoxibIBA 01/2012
1	Prostaglandins EIBA 01/2012
1	Celecoxib (Celebrex)FDA Link 01/2012
1	SC 560IBA 01/2012
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2012
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2008
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2008
1	PPAR alphaIBA 02/2005
1	Fibric Acids (Fibrates)IBA 02/2005
1	BenzenesulfonamidesIBA 09/2004

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2010
1	Drug Therapy (Chemotherapy) 01/2020
1	Injections 03/2017
1	Precision Medicine 01/2016